| Type: |
Conjugated Primary Antibody |
| Conjugated with: |
594, ALEXA FLUOR® |
| Host organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Protein/Peptide: |
Apolipoprotein CI/APOC1 |
| Specificity: |
This antibody reacts specifically with Apolipoprotein CI/APOC1 |
| Modification: |
No modification has been applied to this antibody |
| Modification site: |
None |
| Clonality: |
Polyclonal Antibody |
| Clone: |
Polyclonal Antibodies |
| Concentration: |
1ug per 1ul |
| Antigen Source: |
KLH conjugated synthetic peptide derived from human Apolipoprotein CI/APOC1 |
| Gene ID: |
341 |
| Applications: |
IF(IHC-P) |
| Applications with corresponding dilutions: |
IF(IHC-P)(1:50-200) |
| Cross reactive species: |
Mouse (Mus musculus), Rat (Rattus norvegicus), Human (Homo sapiens) |
| Cross Reactive Species details: |
However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species, No significant cross reactivity has been observed for this antibody for the tested species |
| Background information: |
The apolipoprotein C gene family encodes four homologous proteins designated apoC-I to -IV, The human apoC-I gene maps to chromosome 19q13, The human apoC-II gene maps to chromosome 19q13, The human apoC-III gene maps to chromosome 11q23 and encodes a protein that may delay catabolism of triglyceride-rich particles by inhibiting lipoprotein lipase and hepatic lipase, The human apoC-IV gene maps to chromosome 19q13, the enzyme that hydrolyzes triglycerides in plasma and transfers the fatty acids to tissues, which specifically modulate the metabolism of triglyceride-rich lipoproteins, 2 and encodes a 127 amino acid protein that is primarily expressed in the liver, 2 and encodes a 79 amino acid single chain protein that is a necessary cofactor for the activation of lipoprotein lipase, 2 and is expressed primarily in the liver where it is activated when monocytes differentiate into macrophages, Apolipoproteins are protein components of plasma lipoproteins |
| Purification method: |
Purified by Protein A |
| Storage: |
50% glycerol and 0, Store at 4°, 09% sodium azide, C for 12 months, Water buffered solution containing 100ug/ml BSA |
| Excitation emission: |
590nm/617nm |
| Also known as: |
Apolipoprotein CI/APOC1 Antibody |
| Other name: |
Anti-Apolipoprotein CI/APOC1 |
| Advisory: |
For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube, Prior to use briefly centrifuge the vial to gather all the solution on the bottom, specificity and sensitivity, thus reducing its reactivity, Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody |
| Properties: |
For facs or microscopy Alexa 1 conjugate |
| Conjugation: |
Alexa Fluor |
| Gene target: |
Apolipoprotein CI/APOC1 |
| Short name: |
Fluor 594, Anti-Apolipoprotein CI/APOC1 |
| Label: |
ALEXA |
| Alternative name: |
ALEXA Fluor 594, antibody to-Apolipoprotein CI/apolipoprotein C-I |
| Alternative to gene target: |
APOC1 and IDBG-56839 and ENSG00000130208 and 341, Apoc1 and IDBG-152061 and ENSMUSG00000040564 and 11812, Extracellular, phosphatidylcholine-sterol O-acyltransferase activator activity, this GO :0004859 and phospholipase inhibitor activity and molecular function this GO :0005504 and fatty acid binding and molecular function this GO :0005576 and extracellular region and cellular component this GO :0005783 and endoplasmic reticulum and cellular component this GO :0006629 and lipid metabolic process and biological process this GO :0006641 and triglyceride metabolic process and biological process this GO :0008203 and cholesterol metabolic process and biological process this GO :0010873 and positive regulation of cholesterol esterification and biological process this GO :0010900 and negative regulation of phosphatidylcholine catabolic process and biological process this GO :0010916 and negative regulation of very-low-density lipoprotein particle clearance and biological process this GO :0031210 and phosphatidylcholine binding and molecular function this GO :0032374 and regulation of cholesterol transport and biological process this GO :0032375 and negative regulation of cholesterol transport and biological process this GO :0033344 and cholesterol efflux and biological process this GO :0033700 and phospholipid efflux and biological process this GO :0034361 and very-low-density lipoprotein particle and cellular component this GO :0034364 and high-density lipoprotein particle and cellular component this GO :0034369 and plasma lipoprotein particle remodeling and biological process this GO :0034375 and high-density lipoprotein particle remodeling and biological process this GO :0034379 and very-low-density lipoprotein particle assembly and biological process this GO :0034382 and chylomicron remnant clearance and biological process this GO :0034447 and very-low-density lipoprotein particle clearance and biological process this GO :0042157 and lipoprotein metabolic process and biological process this GO :0042627 and chylomicron and cellular component this GO :0043085 and positive regulation of catalytic activity and biological process this GO :0045717 and negative regulation of fatty acid biosynthetic process and biological process this GO :0045833 and negative regulation of lipid metabolic process and biological process this GO :0048261 and negative regulation of receptor-mediated endocytosis and biological process this GO :0050995 and negative regulation of lipid catabolic process and biological process this GO :0051005 and negative regulation of lipoprotein lipase activity and biological process this GO :0055102 and lipase inhibitor activity and molecular function this GO :0060228 and phosphatidylcholine-sterol O-acyltransferase activator activity and molecular function this GO :0070062 and extracellular vesicular exosome and cellular component, this GO :0004859 : phospholipase inhibitor activity, this GO :0004859 : phospholipase inhibitor activity and also this GO :0005504 : fatty acid binding and also this GO :0031210 : phosphatidylcholine binding and also this GO :0055102 : lipase inhibitor activity and also this GO :0060228 : phosphatidylcholine-sterol O-acyltransferase activator activity, this GO :0005504 : fatty acid binding, this GO :0031210 : phosphatidylcholine binding, this GO :0055102 : lipase inhibitor activity, this GO :0060228 : phosphatidylcholine-sterol O-acyltransferase activator activity, apolipoprotein C-I |
| Identity: |
607 |
| Gene: |
APOC1 |
More about : APOC1 |
| Long gene name: |
apolipoprotein C1 |
| Synonyms gene name: |
apolipoprotein C-I |
| Locus: |
19q13, 32 |
| Discovery year: |
2001-06-22 |
| GenBank acession: |
X00570 |
| Entrez gene record: |
341 |
| Classification: |
Apolipoproteins |
| Havana BLAST/BLAT: |
OTTHUMG00000180844 |